Vimarsana
Biggest News Aggregation in the World

Never Smokers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Never Smokers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Never Smokers Today - Breaking & Trending Today

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan - Vimarsana News

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer...

ICYMI: Highlights From CHEST 2023 - Vimarsana News

ICYMI: Highlights From CHEST 2023

Our top coverage from the CHEST Annual Meeting 2023 explored various topics, including strategies to prevent air pollutant exposure and keys to achieving equity in lung cancer screenings.

Source: ajmc.com
Former Smokers Who Kick the Habit See Survival Benefits Grow With Time - Vimarsana News

Former Smokers Who Kick the Habit See Survival Benefits Grow With Time

Two decades after quitting, the CV death risk matched that of never smokers, but clinicians should be alert in the early years.

Source: tctmd.com
The Engineer - Chest X-rays and AI identify non-smokers at risk of lung cancer - Vimarsana News

The Engineer - Chest X-rays and AI identify non-smokers at risk of lung cancer

Chest X-rays and artificial intelligence have been used to identify non-smokers who are at high risk for lung cancer.

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial - Vimarsana News

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial

BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With